Swixx BioPharma significantly expands its market reach in Latin America by acquiring Biopas, enhancing its presence in neurology, oncology, and other therapeutic areas.

Swixx BioPharma, based in Baar, Switzerland, announces its strategic expansion into Latin America by acquiring 100% of Pharma Consulting Group SA, the holding company of Laboratorios Biopas SA. Biopas, headquartered in Bogota, Colombia, is a leading independent marketing and sales company for international biopharmaceutical firms in Latin America.

The acquisition, expected to close by June-July 2024 pending regulatory approvals, adds $220 million in sales volume, over 300 new employees, and therapeutic coverage in neurology, oncology, immunology, gastroenterology, rare diseases, and specialty areas to Swixx’s portfolio.

This acquisition follows Swixx BioPharma’s recent entry into the Middle East market in September 2023 and represents another step in becoming the partner of choice for biopharmaceutical companies seeking indirect market routes. Biopas operates in 20 countries, including Argentina, Brazil, Chile, Colombia, and Mexico. The management team of Biopas will continue to lead the combined entity’s operations in Latin America, maintaining the Biopas name under the Swixx BioPharma Group.

Benoit Chastaing, Non-Executive Board Member of Swixx BioPharma and Managing Partner at Merieux Equity Partners, praised the acquisition as a transformative step, offering a comprehensive multi-continental partnership for biopharmaceutical companies. Pascal Forget, co-founder of Biopas, echoed this sentiment, emphasizing the shared mission to improve access to innovative medicines in Latin America.

Swixx BioPharma operates branches in Central and Eastern Europe, Greece, Russia, and several Eurasian countries, including Belarus, Kazakhstan, Uzbekistan, and the Middle East. The company employs over 1,300 people and expects to generate sales exceeding one billion euros in 2024.

©Keystone-SDA